the vaccine

[키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV
[DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial